SCYNEXIS Executes 1-for-8 Reverse Stock Split for Nasdaq Compliance
SCYX sits 25% above its 52-week low of $0.565.
Summary
SCYNEXIS completed a 1-for-8 reverse stock split to meet Nasdaq listing requirements, with split-adjusted trading beginning June 1, 2026. The company also reduced its authorized shares, avoiding a previously proposed larger increase.
Key Events · Corporate Governance and Compliance · SCYX
-
Reverse Stock Split Executed
A 1-for-8 reverse stock split of common stock became effective on May 29, 2026, consolidating shares and increasing the per-share price.
-
Nasdaq Trading Adjustment
Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market starting June 1, 2026, under the existing ticker symbol SCYX.
-
Compliance and Delisting Avoidance
This action is crucial for the company to meet Nasdaq's minimum bid price requirement, thereby preventing potential delisting.
-
Authorized Share Reduction
The total number of authorized common shares was reduced from 150,000,000 to 18,750,000 (post-split), effectively maintaining the pre-split equivalent of 150,000,000 shares and avoiding a previously proposed increase to 300,000,000 shares.
Analysis · SCYX · Life Sciences
SCYNEXIS has finalized and executed a 1-for-8 reverse stock split, a critical step to increase its share price and regain compliance with Nasdaq's minimum bid price requirement. This action prevents potential delisting, which is a significant risk for the company. Additionally, the company reduced its authorized shares to an equivalent of 150 million pre-split, avoiding a previously proposed increase to 300 million, which mitigates future dilution concerns for shareholders.
At the time of this filing, SCYX was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.